Papers
1
Total Citations
2
H-Index
1
About
Zhiyong Huang is a clinical oncology researcher whose work centers on hepatocellular carcinoma (HCC) treatment, with a particular focus on innovative perioperative therapeutic strategies that combine immunotherapy with targeted agents. His most notable contribution examines the combination of TQB2450, a PD-L1 immune checkpoint inhibitor, with anlotinib — a multi-target tyrosine kinase inhibitor — as a perioperative treatment approach for HCC patients at elevated risk of recurrence. This prospective, single-arm Phase Ib study represents a meaningful step forward in addressing one of oncology's most pressing challenges: reducing post-surgical relapse rates in liver cancer, a disease notorious for its poor prognosis and high recurrence burden. By investigating this novel combinatorial regimen in a structured clinical framework, Huang and his collaborators are helping to define new standards of care at the intersection of immuno-oncology and surgical oncology. Though his work is in its early citation trajectory, the clinical relevance of his research positions it as a valuable reference point for researchers and clinicians navigating the rapidly evolving landscape of HCC management and perioperative systemic therapy.
Research Focus
Key Achievements
Top Papers
- 1